Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.99%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.03%
#4 clBTC clBTC +12.26%
#5 OpenEden OpenEden +10.90%
#6 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.95%
#7 MarsCoin MarsCoin +8.78%
#8 Mantle Staked Ether Mantle Staked Ether +8.43%
#9 Mantle Restaked ETH Mantle Restaked ETH +8.23%
#10 Akedo Akedo +8.03%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
BioSyntech, Inc. BioSyntech, Inc.

BioSyntech, Inc.

BSYI
Rangering i aksjer #40152
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels... BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology to precisely deliver biotherapeutics. Its technological assets also include Arthro-BST, an arthroscopic device for the non-destructive evaluation of cartilage degradation or repair, and Mach-1, a micromechanical testing system for assessing the properties of various tissues and materials. The company also manufactures ultra-pure chitosans under the Ultrasan brand and offers both manufacturing and analytical services. Founded in 1994 and based in Laval, Canada, BioSyntech Inc. initiated administration proceedings under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently undergoing reorganization.
Aksjekurs
$0.00001
Sist synkronisert: 2025-09-24
Markedsverdi
$229.03K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
CA
Handel BioSyntech, Inc. (BSYI)

Kategori

Healthcare
P/E-forhold for BioSyntech, Inc. (BSYI)
P/E-forhold per 2026 TTM: 0
Ifølge BioSyntech, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for BioSyntech, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.